Tirzepatide Clinical Reference

Tirzepatide is the most studied dual incretin receptor agonist in clinical medicine. Across the SURPASS program for type 2 diabetes and the SURMOUNT program for chronic weight management and obstructive sleep apnea, more than 10,000 adults have been studied in pivotal phase 3 trials. The clinical reference pages below summarize the mechanism, trial outcomes, safety profile, drug interactions, dosing recommendations, and cardiovascular evidence as it stands in 2026. All content is built from FDA prescribing information, published trial reports, and established pharmacology literature — with the understanding that clinical decisions belong to a licensed clinician familiar with the patient's full medical history.

All pages in this section

Mechanism of action — Tirzepatide is the first-in-class dual GIP and GLP-1 receptor agonist. Activation of both incretin pathways produces synergistic effects on insulin secretion, glucagon suppression, gastric emptying, and central appetite regulation — the leading hypothesis for tirzepatide's superior outcomes versus GLP-1 monoagonists.
SURMOUNT trial program — Pivotal phase 3 trials for chronic weight management and obstructive sleep apnea. SURMOUNT-1, SURMOUNT-2, SURMOUNT-3, SURMOUNT-4 (withdrawal), SURMOUNT-OSA (sleep apnea), and SURMOUNT-5 (head-to-head vs semaglutide 2.4 mg).
SURPASS trial program — Pivotal phase 3 trials for type 2 diabetes. SURPASS-1 through SURPASS-5, including SURPASS-2 head-to-head vs semaglutide 1 mg and SURPASS-4 cardiovascular safety analysis.
Cardiovascular outcomes — Tirzepatide's cardiovascular effects, the ongoing SURPASS-CVOT trial, the SUMMIT trial in HFpEF with obesity, and how tirzepatide compares to semaglutide for established cardiovascular benefit.
Contraindications & boxed warnings — Absolute contraindications (MTC, MEN 2, pregnancy, hypersensitivity) and relative contraindications (gastroparesis, prior pancreatitis, severe renal impairment, active diabetic retinopathy).
Drug interactions — Oral contraceptive interaction (clinically important during titration), insulin/sulfonylurea combinations, narrow-therapeutic-index oral medications, and the absence of CYP-mediated interactions due to tirzepatide's peptide structure.
Side effects in detail — Gastrointestinal adverse events, pancreatitis, gallbladder events, kidney injury, hypersensitivity, retinopathy, suicidal ideation monitoring, and the boxed thyroid C-cell tumor warning — with mitigation strategies.
Dosing & pharmacology — Standard titration schedule (2.5 mg → 15 mg), pharmacokinetic profile (terminal half-life ~5 days), dose selection guidance, missed-dose handling, and storage requirements.

Frequently asked questions

How effective is tirzepatide compared to other GLP-1 medications?

Tirzepatide consistently produces greater A1C and weight reductions than GLP-1 monoagonists in head-to-head and indirect comparisons. SURPASS-2 directly compared tirzepatide to semaglutide 1 mg in type 2 diabetes, showing superiority for all three tirzepatide doses on A1C and weight endpoints. SURMOUNT-5 demonstrated superior weight loss versus semaglutide 2.4 mg in obesity.

Is tirzepatide approved for both diabetes and weight loss?

Yes, under two brand names. Mounjaro (Eli Lilly) is FDA-approved for type 2 diabetes (May 2022). Zepbound (Eli Lilly) is FDA-approved for chronic weight management (November 2023) and for moderate-to-severe obstructive sleep apnea in obesity (December 2024). Both contain the same active ingredient, tirzepatide.

What clinical monitoring is recommended on tirzepatide?

Baseline and periodic assessment of: renal function (eGFR), liver enzymes, glycemic markers in diabetic or prediabetic patients, gallbladder symptoms, signs of pancreatitis, mood and suicidal ideation, and pregnancy status in patients of reproductive potential. Thyroid examination if clinically indicated by symptoms or risk factors.

Are compounded forms of tirzepatide clinically equivalent to brand-name?

No head-to-head trials have established clinical equivalence between compounded tirzepatide and brand-name Mounjaro or Zepbound. Some patients report comparable outcomes; others have reported issues with potency variability or injection-site reactions. Brand-name products carry FDA pre-market review, standardized formulation, and consistent quality controls that compounded products do not.